title: Acute Effects of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Segment Elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
abstract: We evaluated the acute effect of intracoronary administration of tirofiban on no-reflow phenomenon in patients with ST-segment elevated myocardial infarction undergoing primary percutaneous coronary intervention. Consecutive patients (n = 162) were randomized into 2 groups based on whether intracoronary tirofiban was administered. After the administration of intracoronary tirofiban, thrombolysis in myocardial infarction (TIMI) flow grade significantly increased (P < .001) and successful reperfusion was achieved in 26 (32%) patients. In the placebo group, however, after the administration of intracoronary placebo the TIMI flow grade did not change (P = .070), and successful reperfusion was achieved only in 8 (10%) patients. In-hospital major adverse cardiac events (MACE) were significantly lower in the tirofiban group (36% vs 19%, P = .013). Intracoronary administration of tirofiban significantly improves TIMI flow grade and is associated with a lower in-hospital rate of MACE.
authors.affiliation: Department of Cardiology, Kayseri Education and Research Hospital, Kayseri, Turkey mahmutakpek@yahoo.com.
authors.forename: Mahmut
authors.initials: M
authors.lastname: Akpek
authors.affiliation: Department of Cardiology, Kayseri Education and Research Hospital, Kayseri, Turkey.
authors.forename: Omer
authors.initials: O
authors.lastname: Sahin
authors.affiliation: Department of Cardiology, Kayseri Education and Research Hospital, Kayseri, Turkey.
authors.forename: Bahadir
authors.initials: B
authors.lastname: Sarli
authors.affiliation: Department of Cardiology, Kayseri Education and Research Hospital, Kayseri, Turkey.
authors.forename: Ahmet Oguz
authors.initials: AO
authors.lastname: Baktir
authors.affiliation: Department of Cardiology, Kayseri Education and Research Hospital, Kayseri, Turkey.
authors.forename: Hayrettin
authors.initials: H
authors.lastname: Saglam
authors.affiliation: Department of Cardiology, Erciyes University School of Medicine, Kayseri, Turkey.
authors.forename: Serkan
authors.initials: S
authors.lastname: Urkmez
authors.affiliation: Department of Cardiology, Erciyes University School of Medicine, Kayseri, Turkey.
authors.forename: Ali
authors.initials: A
authors.lastname: Ergin
authors.affiliation: Department of Cardiology, Erciyes University School of Medicine, Kayseri, Turkey.
authors.forename: Abdurrahman
authors.initials: A
authors.lastname: Oguzhan
authors.affiliation: Department of Cardiology, Kayseri Education and Research Hospital, Kayseri, Turkey.
authors.forename: Huseyin
authors.initials: H
authors.lastname: Arinc
authors.affiliation: Department of Cardiology, Erciyes University School of Medicine, Kayseri, Turkey.
authors.forename: Mehmet G
authors.initials: MG
authors.lastname: Kaya
mesh_terms: D000368:Aged; D003326:Coronary Circulation / Q000187:drug effects*; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D054318:No-Reflow Phenomenon / Q000175:diagnosis / Q000209:etiology / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D012008:Recurrence; D012307:Risk Factors; D015607:Stents; D013997:Time Factors; D000077466:Tirofiban; D016896:Treatment Outcome; D014421:Turkey; D014443:Tyrosine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D010975:Platelet Aggregation Inhibitors; D014443:Tyrosine; D000077466:Tirofiban
keywords: ST-segment elevated myocardial infarction; no-reflow phenomena; tirofiban